2646 completed. 2646 Phase 2, 428 Phase 1, 221 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2646 | Completed 2646 |
| Phase 1 | 428 | Completed 428 |
| Phase 3 | 221 | Completed 221 |
Follow Brain Diseases: new trials by email Literature Review of Brain Diseases trials Research Report on Brain Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fisetin in Mild Alzheimer's Disease Fisetin - Alzheimer s Disease, Alzheimer Dementia | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 5 | 2026-01-27 | 2026-08-20 |
| CAROTID STABILISE Pilot: Alirocumab for Symptomatic Carotid Stenosis Alirocumab, Matching placebo - Carotid Artery Stenosis | Phase 2 | Completed | Middle East North Africa Stroke and Interventional Neurotherapies Organization | 40 | 2026-01-06 | 2026-11-16 |
| HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. HRS-7450 Injection, HRS-7450 Injection Placebo - Acute Ischemic Stroke | Phase 2 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 210 | 2025-10-31 | 2026-10-20 |
| Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke Ivolumab 420mg (three vials) - Acute Stroke | Phase 2 | Completed | The Affiliated Hospital of Xuzhou Medical University | 132 | 2025-10-30 | 2026-09-10 |
| Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) A-DOPAMINE - Parkinson Disease | Phase 1 / Phase 2 | Completed | University Hospital, Lille | 1 | 2025-10-01 | 2026-05-22 |
| A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke MT200605, Placebo - Acute Ischemic Stroke | Phase 2 | Completed | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 360 | 2025-09-30 | 2026-11-12 |
| Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) aspirin + clopidogrel, Aspirin - Acute Ischemic Stroke | Phase 2 | Completed | University of Alberta | 3 | 2025-09-02 | 2026-07-16 |
| A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria JNT-517 Tablet, Placebo - Phenylketonuria (PKU) | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | 2025-07-16 | 2026-05-13 |
| Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride New TETA 4HCl Formulation, Standard of Care - Wilson's Disease | Phase 2 | Completed | Orphalan | 10 | 2025-07-15 | 2026-04-06 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Placebo, ML-007C-MA BID, ML-007C-MA QD - Schizophrenia | Phase 2 | Completed | MapLight Therapeutics | 307 | 2025-06-27 | 2026-07-09 |
| A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke Neflamapimod, Placebo - Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke | Phase 2 | Completed | EIP Pharma Inc | 45 | 2025-06-20 | 2026-10-28 |
| A Study to Assess TTI-0102 vs Placebo in MELAS Patients TTI-0102, Placebo - MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS) | Phase 2 | Completed | Thiogenesis Therapeutics, Inc. | 9 | 2025-05-12 | 2026-07-24 |
| Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease levodopa-carbidopa, Silymarin - Parkinson Disease | Phase 2 | Completed | Tanta University | 50 | 2025-05-10 | 2026-11-04 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease ONO-2020, Placebo - Alzheimer Disease | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 260 | 2025-04-24 | 2026-10-22 |
| BCAAs in Concussion 2.0 BCAA, Placebo - Concussion, Brain, Concussion, Mild | Phase 2 | Completed | Akiva Cohen | 17 | 2025-04-01 | 2026-09-03 |
| A Study of NE3107 in Early Parkinson's NE3107, Placebo - Parkinsons Disease (PD) | Phase 2 | Completed | BioVie Inc. | 57 | 2025-03-26 | 2026-08-11 |
| A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke OTR4132, Placebo - Endovascular Thrombectomy, Ischemic Cerebrovascular Accident | Phase 2 | Completed | Organ, Tissue, Regeneration, Repair and Replacement | 60 | 2025-03-14 | 2026-06-26 |
| A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Completed | NeuroPro Therapeutics, Inc. | 14 | 2025-03-11 | 2026-09-28 |
| A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg - Migraine | Phase 2 | Completed | TriGemX Bio, Inc. | 431 | 2025-03-11 | 2026-11-16 |
| A Study of NTRX-07 in Participants With Alzheimer's Disease NTRX-07, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Completed | NeuroTherapia, Inc. | 48 | 2025-03-01 | 2026-10-29 |
Showing 20 of 2646. Sign in to see all of them.
Alzheimer Disease (414) · Brain Neoplasms (374) · Parkinson Disease (362) · Stroke (312) · Glioblastoma (192) · Ischemic Stroke (150) · Epilepsy (131) · Dementia (128) · Gliosarcoma (123) · Glioma (120) · Migraine Disorders (110) · Central Nervous System Neoplasms (109) · Astrocytoma (102) · Cognitive Dysfunction (102) · Oligodendroglioma (80)
Nervous System Diseases (2613) · Central Nervous System Diseases (2603) · Neurodegenerative Diseases (942) · Pathological Conditions, Signs and Symptoms (650) · Mental Disorders (627) · Cardiovascular Diseases (586) · Vascular Diseases (583) · Neurocognitive Disorders (555) · Cerebrovascular Disorders (540) · Basal Ganglia Diseases (486) · Movement Disorders (466) · Tauopathies (419) · Dementia (418) · Neoplasms (411)
Temozolomide (63) · Bevacizumab (49) · Sodium Chloride (41) · Saline Solution (35) · Radiotherapy (30) · Donepezil (27) · Levodopa (25) · Transcranial Direct Current Stimulation (23) · Irinotecan (22) · Aspirin (20) · Levetiracetam (19) · carbidopa, levodopa drug combination (19) · Botulinum Toxins, Type A (18) · Cyclophosphamide (18) · Carboplatin (17)
National Cancer Institute (NCI) (51) · National Institute of Neurological Disorders and Stroke (NINDS) (45) · Duke University (39) · Pfizer (35) · Novartis Pharmaceuticals (27) · Eli Lilly and Company (23) · Assistance Publique - Hôpitaux de Paris (19) · US Department of Veterans Affairs (18) · Genzyme, a Sanofi Company (17) · GlaxoSmithKline (17) · UCB Pharma (17) · Chang Gung Memorial Hospital (16) · VA Office of Research and Development (16) · Avid Radiopharmaceuticals (15) · M.D. Anderson Cancer Center (15)
United States (1543) · France (253) · Germany (251) · Canada (240) · United Kingdom (234) · Spain (185) · Italy (164) · Australia (141) · Netherlands (118) · China (100) · Poland (94) · Japan (82) · Belgium (80) · Sweden (64) · Austria (63)
PMID 37870112, PMID 33175411, PMID 36602886, PMID 38588457, PMID 35305920, PMID 19775921, PMID 25918556, PMID 27657681, PMID 28403842, PMID 33974419, PMID 34532852, PMID 39800465, PMID 22163120, PMID 24144944, PMID 32593547, PMID 33189083, PMID 36463457, PMID 37059702, PMID 38114596, PMID 38706271, PMID 40368603, PMID 40680102, PMID 41114449, PMID 11112243, PMID 16135345, PMID 17175134, PMID 17941858, PMID 18296121, PMID 18662331, PMID 19453963, PMID 20548058, PMID 21484867, PMID 21586746, PMID 22474060, PMID 22520687, PMID 22738918, PMID 22961727, PMID 23176611, PMID 24001701, PMID 24144615, PMID 24524452, PMID 24711047, PMID 25098701, PMID 25378424, PMID 25677596, PMID 25726502, PMID 25731629, PMID 25744676, PMID 25988365, PMID 26603732
2014 (29), 2015 (21), 2009 (17), 2017 (17), 2018 (16), 2008 (15), 2016 (14), 2019 (12), 2023 (8), U01CA062399 (8), 2004 (7), 2005 (6), U10CA025224 (6), U10CA021661 (5), U01CA062475 (4)